Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc to Stop Co-development and Commercialization Alliance on FLT3 Tyrosine Kinase Inhibitor with Ambit Biosciences Corporation


Monday, 11 Mar 2013 10:00pm EDT 

Astellas Pharma Inc announced that it has decided to stop the co-development and commercialization alliance on FLT3 tyrosine kinase inhibitor with Ambit Biosciences Corporation, effective September 3, 2013. The alliance was formed in 2009. 

Company Quote

1713.0
3.0 +0.18%
25 Dec 2014